Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine

AIDS

Volumn 15, Issue 6, 2001, Pages 799-800

  Moyle, G J ^a   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ARTICLE; DRUG RESISTANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DIDANOSINE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STAVUDINE;

EID: 0035853439     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00017     Document Type: Article

References (6)

1. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
2. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history
3. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
4. Drug resistance and virologic response to NUCA3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
5. Occurrence of thymidine associated mutations in naive patients treated with more than 6 months of stavudine/lamivudine bitherapy combination and tritherapies includine stavudine/didanosine or stavudine/lamivudine
6. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy